Popovsky Mark A

Average Profitability
4.13%
Insider Buys Quantity
7
Insider Buys Sum
$137,876.88
Insider Sells Quantity
5
Insider Sells Sum
$2.68M

Insider Activity of Popovsky Mark A

The largest purchase of all time was on 2005-05-02 and amounted to 882 shares of Haemonetics Corporation for $23,990.

The largest sale of all time was on 2007-02-02 and amounted to 20000 shares of Haemonetics Corporation for $705,088.

Biography of Popovsky Mark A

No biography is available at this moment.

2008-05-01PurchaseHaemonetics Corporation
HAE
VP, Corporate Medical Director
492
0.0016%
$44.35$21,822+4.75%
2008-01-02SaleHaemonetics Corporation
HAE
VP, Corporate Medical Director
10,000
0.0268%
$44.04$440,425-7.45%
2007-11-01PurchaseHaemonetics Corporation
HAE
VP, Corporate Medical Director
506
0.0015%
$40.66$20,576+10.8%
2007-07-02SaleHaemonetics Corporation
HAE
VP, Corporate Medical Director
14,000
0.039%
$37.75$528,536+5.7%
2007-05-01PurchaseHaemonetics Corporation
HAE
VP, Corporate Medical Director
564
0.0017%
$38.63$21,789+10.6%
2007-04-25SaleHaemonetics Corporation
HAE
VP, Corporate Medical Director
14,000
0.0386%
$35.36$495,032+9.65%
2007-02-02SaleHaemonetics Corporation
HAE
VP, Corporate Medical Director
20,000
0.0556%
$35.25$705,088+5.51%
2006-11-01PurchaseHaemonetics Corporation
HAE
VP, Corporate Medical Director
456
0.0015%
$38.76$17,675+6.2%
2006-05-01PurchaseHaemonetics Corporation
HAE
VP, Corporate Medical Director
258
0.0007%
$41.52$10,713-14.03%
2006-02-02SaleHaemonetics Corporation
HAE
Vp, Corporate Medical Director
14,000
0.0371%
$36.46$510,432-4.62%
2005-11-01PurchaseHaemonetics Corporation
HAE
Vp, Corporate Medical Director
594
0.0016%
$35.88$21,313-0.44%
2005-05-02PurchaseHaemonetics Corporation
HAE
Vp, Corporate Medical Director
882
0.0022%
$27.20$23,990+11%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.